24/7 Market News Snapshot 07 July, 2025 – Cogent Biosciences, Inc. Common Stock (NASDAQ:COGT)

July 7, 2025

DENVER, Colo., 07 July, 2025 (www.247marketnews.com) – (NASDAQ:COGT) are discussed in this article.
Cogent Biosciences, Inc. (COGT) has experienced a significant surge in its stock value, soaring approximately 29.13% from a previous closing price of $7.58 to an opening of $8.97 and reaching a peak of $9.79. This dramatic increase has energized investors, with a notable trading volume of 12.80 million shares being exchanged. Market analysts attribute this excitement to rising interest in Cogent’s innovative developments, particularly in the biotech sector.

At the forefront of Cogent’s recent advances is the successful outcome of the SUMMIT clinical trial for its investigational therapy, bezuclastinib, targeting non-advanced systemic mastocytosis (NonAdvSM). In the registration-directed Part 2 of this trial, bezuclastinib demonstrated a mean change of 24.3 points in the total symptom score (TSS) at the 24-week mark, significantly outperforming the placebo group which recorded only a 15.4 point change. This results in a placebo-adjusted difference of 8.91 points, achieving statistical significance (p=0.0002).

Moreover, 87.4% of patients treated with bezuclastinib showed at least a 50% reduction in serum tryptase levels, emphasizing its therapeutic efficacy compared to the placebo, in which no similar reductions were observed. The favorable safety and tolerability profile of bezuclastinib supports its potential for chronic administration, positioning it as a promising candidate for the treatment of NonAdvSM.

Cogent plans to file its New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for bezuclastinib by late 2025. In addition, Cogent intends to host an investor conference call to elaborate on these promising findings. As the company prepares for future study presentations, including pivotal results concerning treatments for gastrointestinal stromal tumors and advanced systemic mastocytosis expected later in 2025, it reaffirms its dedication to pioneering new therapeutic options for patients with challenging conditions.

Related news for (COGT)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.